Journal Facts

Journal
BoneKEy Reports
ISSN
2047-6396
Volume
4
Year
2015

Article Facts

Title
Cancer-targeted therapies and radiopharmaceuticals
DOI
10.1038/bonekey.2015.76
Authors

Tilman D Rachner
Franz Jakob
Lorenz C Hofbauer

Online Date
06/03/2015

Article Links

BoneKEy Reports | Reviews

Cancer-targeted therapies and radiopharmaceuticals

Tilman D Rachner
Franz Jakob
Lorenz C Hofbauer


DOI:10.1038/bonekey.2015.76

Abstract

The treatment of bone metastases remains a clinical challenge. Although a number of well-established agents, namely bisphosphonates and denosumab, are available to reduce the occurrence of skeletal-related events, additional cancer-targeted therapies are required to improve patients’ prognosis and quality of life. This review focuses on novel targets and agents that are under clinical evaluation for the treatment of malignant bone diseases such as activin A, src and endothelin-1 inhibition or agents that are clinically approved and may positively influence bone, such as the mTOR inhibitor everolimus. In addition, the potential of alpharadin, a novel radiopharmaceutical approved for the treatment of prostatic bone disease, is discussed.

Creative Commons License This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.